Target treatment with stereotactic radiation for recurrent gliomas

Authors

Ayesha Ali, Thomas Jefferson UniversityFollow
Victor E. Chen, Thomas Jefferson UniversityFollow
Claire Zurlo, Thomas Jefferson UniversityFollow
James M Taylor, Thomas Jefferson UniversityFollow
Christian Fernandez, Thomas Jefferson UniversityFollow
Wenyin Shi, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

12-1-2020

Comments

This article is the author’s final published version in Chinese Clinical Oncology, Volume 9, Issue 6, December 2020, Article number 74.

The published version is available at https://doi.org/10.21037/cco.2020.03.05. Copyright © Chinese Clinical Oncology.

Abstract

High grade gliomas (HGG) have a propensity to recur locally and have poor outcomes. As such, safe and effective treatment is paramount. Target treatment with stereotactic radiation allows safe re-irradiation through minimizing normal brain tissue radiation due to its high precision. In this review, we evaluated the clinical experiences using SRS and FSRT for re-irradiation in HGG. We report the radiobiological advantages and disadvantages of both modalities as well as the safety and efficacy published in current literature.

Recommended Citation

Ali, Ayesha; Chen, Victor E.; Zurlo, Claire; Taylor, James M; Fernandez, Christian; and Shi, Wenyin, "Target treatment with stereotactic radiation for recurrent gliomas" (2020). Department of Radiation Oncology Faculty Papers. Paper 145.
https://jdc.jefferson.edu/radoncfp/145

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

PubMed ID

32389000

Language

English